European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

First New Osteoporosis Medicine Approved in the European Union (EU) Since 2010 Novel Bone-Builder With a Dual Effect That Increases Bone Formation and Reduces Bone Loss THOUSAND OAKS, Calif. and BRUSSELS, Dec. 11, 2019 -- (Healthcare Sales & Marketin... Biopharmaceuticals, Regulatory Amgen, UCB, EVENITY, romosozumab, osteoporosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news